Compare SGHC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | LNTH |
|---|---|---|
| Founded | 2020 | 1956 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.5B |
| IPO Year | 2021 | 2014 |
| Metric | SGHC | LNTH |
|---|---|---|
| Price | $14.56 | $109.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $17.33 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 3.6M | 842.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $16.09 | N/A |
| Revenue Next Year | $9.73 | $14.19 |
| P/E Ratio | ★ $20.80 | $61.04 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $8.46 | $47.27 |
| 52 Week High | $14.70 | $111.86 |
| Indicator | SGHC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 68.13 |
| Support Level | $10.28 | $95.00 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.54 | 3.08 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 87.78 | 80.78 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's four operating segments-Betway, Spin, Jumpman and DGC. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.